🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline ascopubs.org/doi/10.1200/JC…

Review Article: Cervical Cancer nej.md/41Rw0gb #Oncology

🔥Highlighting comparison of OPRA vs AIO-12 CRT ➡️FOLFOX ➡️surgery vs WW if nCR/cCR 🚨With RCT comparing WW vs TME unlikely, data like these are critical to inform the safety/efficacy of WW We can ⭐️CONFIDENTLY⭐️ advocate for WW in pts w cCR and select pts w nCR #GI25 ASCO

📘Treatment of dMMR/MSI gastro-oesophageal adenocarcinoma ESMO - Eur. Oncology EORTC ✅Excellent review from biology to management 👉doi.org/10.1016/j.ctrv… Lizzy Smyth Angelica Petrillo OncoAlert #cancer #oncology #MedX

Infinity trial: tremelimumab plus durvalumab as neoadjuvant or definitive therapy for dMMR/MSI gastroesophageal cancer. annalsofoncology.org/article/S0923-… 🎯cohort 1: PCR 60% and MPR 80%. 🎯cohort 2: CCR 76%, gastrectomy-free survival 64.2%.

Thrilled to share that I’ve been selected for the ESMO Preceptorship on Gastroesophageal Cancer in Lima, Peru. Honored to learn and connect with oncologists from around the world. #Oncology #ESMO2025 #GastroesophagealCancer #EsmoPreceptorship

Treatment Algorithm: This is the algorithm we’ve used during our 🗣️ w/ joaquim bellmunt for #BladderCancer! This includes #NIAGARA, though we’re still awaiting FDA Oncology approval. #OncTwitter #MedTwitter CancerNetwork®

A few reminders from a GI oncologist during colorectal cancer awareness month: - No adult is “too young” to have cancer. I routinely see pts in their 30-40s w/ symptoms for months & work up was delayed - Don’t ignore anemia or iron deficiency - 45 is the new 50. Get screened!

📝My simplified summary of neoadjuvant-perioperative treatment in GEJ adenocarcinoma ✅For OS ✔️ CRT+Surg > Surg (CROSS) ✔️periECF + Surg > Surg (MAGIC) ✔️periCF + Surg > Surg (FFCD) ✔️ periFLOT > periECF (FLOT4) ✔️periECF + Surg = CRT + Surg (Neo-AEGIS) ✔️periFLOT + Surg > CRT

Post ASCOGI con colegas y amigos ❤️

📗Chemotherapy in MSI-H non-metastatic gastric cancer ACS Journal Cancer ➡️Meta-analysis ❌Perioperative ChT: No OS or DFS benefit ❌Adjuvant ChT: No OS benefit, no DFS benefit in adjusted analysis, no benefit for stage II or III 👉doi.org/10.1002/cncr.3… OncoAlert #cancer

Truly honored to have taken part in the #ESMOPreceptorship on Gastric Cancer — an enriching experience with outstanding colleagues and experts in the field. Grateful for the opportunity to exchange knowledge and dive deep into the latest advances. Thanks ESMO - Eur. Oncology 🙌🏻

Challenges in the management of metastatic colorectal cancer. Important update by Dr. Mendez and the IATTGI team.

Ateneo multidisciplinario en tumores de Via Biliar 💚

2 slides to summarize CtDNA role in early CRC . Excellent 👍. Nice discussion. ASCO Nicholas Hornstein Udhayvir Grewal Dr. Nina Niu Sanford OncoAlert Oncology Brothers #ASCO25

#ASCO2025 #TTDUpdates Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer nejm.org/doi/full/10.10… 👉OS 14.7 vs 11.4 mo HR 0.70 | p=0.004 👉PFS: 6.7 vs 5.6 mo 👉ORR: 44.3% vs 29.1% ILD/pneumonitis in 13.9% HER2 "rebiopsy" post-trastuzumab is mandatory

Lenvatinib + pembrolizumab + CTx vs CTx in advanced, metastatic EC/GEJC #ASCO25 🔎LEAP-015 phs-3 👉ORR 58 vs 44% 👉mPFS 7.3 vs 6.0 mo 👉mOS 12.6 vs 12.9 mo 👉AE ≥3 59% vs 48% 🧐 small ORR & PFS benefit, no OS improvement, disappointing ESMO - Eur. Oncology

A mini-thread for all of SOFT/TEXT 15 year update #ASCO25 1/2

Updated landscape: 1L Chemo-IO Trials in ES-SCLC 🫁 🔹 ASTRUM-005 (Serplulimab) shows most impressive data yet: ✅ OS: 15.8 vs 11.1 mo | HR 0.60 ✅ PFS: 5.8 vs 4.3 mo | HR 0.47 ✅ 4-yr OS: 21.9% vs 7.2% 🛡️ Grade ≥3 AE: 33% → lowest among peers 📊 Median OS in other trials:

🧬 New study highlights germline risks in gastric cancer (GC): 📊 Of 3,706 GC patients tested, 13.3% had pathogenic/likely pathogenic variants (PGVs) 🧠 Most common genes: 🔹 BRCA1/2, PALB2, ATM (HRR) – 35% 🔹 CDH1, CTNNA1 (Hereditary Diffuse GC) – 19.5% 🔹 Lynch syndrome genes –